Your browser doesn't support javascript.
loading
High expression of XPA confers poor prognosis for nasopharyngeal carcinoma patients treated with platinum-based chemoradiotherapy.
Fu, Xiang; Hu, Jiali; Han, Hong-yu; Hua, Yi-jun; Zhou, Ling; Shuai, Wen-di; Du, Wu-ying; Kuang, Chun-mei; Chen, Shuai; Huang, Wenlin; Liu, Ran-yi.
Afiliação
  • Fu X; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
  • Hu J; The Eastern Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Han HY; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
  • Hua YJ; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
  • Zhou L; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
  • Shuai WD; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
  • Du WY; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
  • Kuang CM; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
  • Chen S; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
  • Huang W; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
  • Liu RY; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
Oncotarget ; 6(29): 28478-90, 2015 Sep 29.
Article em En | MEDLINE | ID: mdl-26156020
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Nasofaríngeas / Proteína de Xeroderma Pigmentoso Grupo A Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Oncotarget Ano de publicação: 2015 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Nasofaríngeas / Proteína de Xeroderma Pigmentoso Grupo A Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Oncotarget Ano de publicação: 2015 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos